H. Lundbeck A/S
H. Lundbeck A/S is a global pharmaceutical company, specialising in development of innovative therapeutics for brain disorders.
For more than 70 years, millions of people have been treated with Lundbeck’s products. Furthermore, the development and distribution of the ground-breaking products, targeting psychiatric and neurological disorders, continue to make a difference to people all over the world.
Lundbeck has its headquarters in Denmark, and the company has offices in more than 50 countries around the world. Lundbeck has production facilities in Denmark, France and Italy and research centres in Denmark and the USA. The company has a staff of around 5,400, and its products are registered in more than 100 countries.
H. Lundbeck A/S is listed on NASDAQ Copenhagen. The Lundbeck Foundation owns 69% of the shares in H. Lundbeck, while the remaining 31% are publicly traded.
